What is LiteCure?
LiteCure operates at the intersection of advanced medical engineering and therapeutic recovery, specializing in high-performance laser therapy solutions. The company's core competency lies in photobiomodulation, a non-invasive approach designed to accelerate healing and mitigate pain. Its product portfolio is strategically segmented to address distinct market needs: LightForce Deep Tissue Laser Therapy serves the human medical sector, while Companion Therapy and Pegasus Therapy Lasers cater to the veterinary and equine athletic markets, respectively. By providing drug-free and surgery-free alternatives, LiteCure has established itself as a critical provider for practitioners seeking to enhance patient outcomes through evidence-based light therapy.
The firm's ability to scale across both human and animal health verticals highlights its operational versatility. As the demand for non-pharmacological pain management grows, LiteCure remains positioned as a leader in the development of sophisticated, clinical-grade laser systems that prioritize patient quality of life and recovery efficiency.
How much funding has LiteCure raised?
LiteCure has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in LiteCure
PPP
Public-Private Partnership
What's next for LiteCure?
With the recent infusion of capital, LiteCure is well-positioned to accelerate its research and development initiatives, potentially expanding its footprint in the global medical device market. The strategic allocation of these funds will likely focus on scaling manufacturing capabilities to meet rising demand and deepening its penetration into international veterinary and human healthcare markets. As the company transitions into this next phase of growth, the focus will remain on clinical validation and the continued refinement of its laser therapy platforms to maintain a competitive edge in the rapidly evolving field of regenerative medicine.
See full LiteCure company page
